Xoma Earns $9M As FDA Grants Accelerated Approval To Day One's Ojemda (Tovorafenib) For Relapsed Or Refractory BRAF-Altered Pediatric Low-grade Glioma
Xoma的收入为900万美元,因为美国食品药品管理局加快批准了Ojemda(Tovorafenib)用于复发或难治性BRAF改变的儿科低级神经胶质瘤
Xoma Earns $9M As FDA Grants Accelerated Approval To Day One's Ojemda (Tovorafenib) For Relapsed Or Refractory BRAF-Altered Pediatric Low-grade Glioma
Xoma的收入为900万美元,因为美国食品药品管理局加快批准了Ojemda(Tovorafenib)用于复发或难治性BRAF改变的儿科低级神经胶质瘤
使用浏览器的分享功能,分享给你的好友吧